Navigation Links
Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
Date:5/6/2010

VIENNA, May 6 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

Under the agreed terms Intercell will pay EUR 15 million to Cytos. Intercell will own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates discovered by Cytos. The key scientists, who have very successfully developed the technology at Cytos, will be employed by Intercell. The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®). The AIP® has delivered promising vaccine candidates against Staphylococcus aureus (Phase II/III) and Pneumococcus (Phase I) infections, among others, and has also been the basis for partnerships in the antibody field with Merck & Co. and Kyowa Hakko Kirin in these indications, respectively.

In its future antibody discovery activities Intercell will focus on medically and commercially attractive AIP® derived disease targets including Group B Streptococcus and bacteria involved in hospital acquired infections.

"Cytos' outstanding antibody technology complements our innovative R&D technology platform and enables pipeline progression within our existing portfolio," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Wolfgang Renner, CEO of Cytos, commented: "Intercell, as a leading anti-infective company, is ideally positioned through its Antigen Identification Program (AIP®), to capture the full value of our monoclonal antibody discovery platform. We are very glad that our technology will support Intercell in discovering important new monoclonal antibodies to combat infectious diseases."

Monoclonal antibodies form one of the fastest growing segments of the pharmaceutical industry. The global monoclonal antibodies market was valued at USD 27.4bn in 2008, indicating a Compound Annual Growth Rate (CAGR) of almost 30% between 2000 and 2008.(1)

"Antibodies can be extremely effective for the prevention and treatment of infectious diseases. For example, the increasing rate of antibiotic resistance among certain types of nosocomial pathogens makes it extremely difficult to control hospital acquired infectious diseases in critical situations. Anti-infective antibodies, well known in the medical arena before the advent of antibiotic treatments, have experienced a comeback and monoclonal antibody products are expected to contribute to the control of severe infections that otherwise might be untreatable in the future," explained Eszter Nagy, Senior Vice President Research at Intercell.

(1) http://www.marketresearch.com/product/display.asp?productid=2515126


'/>"/>
SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
4. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician in ... cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a ... first in Arkansas to introduce the most powerful SCS system and the only stretchable ...
(Date:5/26/2017)... Fla. (PRWEB) , ... May 26, 2017 , ... ... of premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that ... your menus. , “Boar’s Head fresh sliced meats and cheeses featured in ...
(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... ... Cross”: the personal journey of Bob Massey and his faith in the Lord. “THE ... Massey. Bob Massey is small in stature but big in character. As Johnny ... others is apparent in all of his life decisions. , “I’m in the eightieth ...
Breaking Medicine News(10 mins):